Vor Biopharma Inc expected to post a loss of 60 cents a share - Earnings Preview

Vor Biopharma

10/03/2023 11:02

* Vor Biopharma Inc  VOR.OQ   VOR.O  is expected to show no
change
in quarterly revenue when it reports  results on March 13
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Vor Biopharma Inc
is for
a loss of 60 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $17.5​, above​ its last closing price of $5.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.60       -0.61      -0.63     Missed  -3.7
 Jun. 30 2022  -0.66       -0.66      -0.58     Beat    11.9
 Mar. 31 2022  -0.52       -0.51      -0.61     Missed  -18.9​
 Dec. 31 2021  -0.52       -0.57      -0.48     Beat    15.2
 ​​Sep.        -0.61       -0.62      -0.50     Beat    19.7
 30 2021                                                
 Jun. 30 2021  -0.47       -0.50      -0.50     Met     0.5​
 Mar. 31 2021  -0.63       -0.62      -0.67     Missed  -7.5
 Dec. 31 2020  -4.29       -4.40      -2.17     Missed  -4,846
                                      hundred           .7
 This summary was machine generated March 10 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated